Relapsed or refractory B-cell Acute Lymphoblastic Leukemia research hub
3 indexed studies · 2 currently recruiting
- recruitingPhase I and Phase II (Integrated)- First administration to humans
Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
This clinical trial is testing a new cell therapy called UCART22 for adults with B-cell acute lymphoblastic leukaemia. It is for people whose cancer has returned or not responded to other treatments. The study aims to find safe doses and see how well the therapy destroys cancer cells.
France · Italy · Spain - active not recruitingPHASE1, PHASE2
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This study looks at a new treatment called AUTO1 for adults with a type of blood cancer called B-cell acute lymphoblastic leukaemia (ALL) that has come back or not responded to previous treatments. It aims to see if AUTO1 is safe and effective.
United States · Spain · United Kingdom - recruitingPHASE1
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This study looks at a new type of cell therapy called CAR T-cell therapy (AUTO1) for children and teenagers with types of blood cancer (leukaemia or lymphoma) that haven't responded to other treatments. It checks how safe and effective it is.
United States · Spain · United Kingdom